Anna Orłowska

Anna Orłowska

Auto-generated profile, based on publicly available information

Anna Orłowska

The University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PL

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025
Verified
Journal Article
Open access
MMMartyna Mocarska
Martyna Mocarska
AMAdrianna Muciek
Adrianna Muciek
JDJulia Dolinkiewicz
Julia Dolinkiewicz
AMAnna Maria Maryńczak
Anna Maria Maryńczak
NNNicole Nitschke
Nicole Nitschke
AOAnna Maria Orłowska
Anna Maria Orłowska
Netherton syndrome (NS) is a rare, autosomal recessive genodermatosis resulting from mutations in the SPINK5 gene, which encodes the LEKTI (Lympho-Epithelial Kazal-type-related inhibitor) protein. This deficiency leads to dysregulated epidermal protease activity, primarily of kallikrein-related peptidases (KLKs), causing severe skin barrier defects, abnormal desquamation, and a complex immune dysregulation involving the TH2 and TH17 pathways. Clinically, NS is characterised by a triad of ichthyosiform erythroderma (often evolving from congenital ichthyosiform erythroderma to ichthyosis linearis circumflexa); pathognomonic hair shaft abnormalities, such as trichorrhexis invaginata ("bamboo hair"); and atopic manifestations with elevated serum IgE. Diagnosis can be challenging due to symptomatic overlap with other inflammatory dermatoses, congenital ichthyosis, and primary immunodeficiencies. Confirmation relies on clinical findings, trichoscopic hair examination, and SPINK5 genetic testing. Management is currently largely supportive, focusing on emollients, antiseptics, and cautious use of topical anti-inflammatory agents. While traditional systemic treatments have limitations, emerging targeted therapies, including biologics and gene therapy, show promise, but require further investigation through robust clinical trials to establish their efficacy and safety. This review highlights the diagnostic intricacies and evolving therapeutic landscape of this complex disorder.

16 December 2024 in Quality in Sport
Verified
Journal Article
Open access
LOLaura Opalska
Laura Opalska
AMAdrianna Muciek
Adrianna Muciek
MMMartyna Mocarska
Martyna Mocarska
AOAnna Orłowska
Anna Orłowska
KSKatarzyna Strakowska
Katarzyna Strakowska
NNNicole Nitschke
Nicole Nitschke
The increasing global prevalence of obesity and type 2 diabetes (T2D) has prompted significant advancements in pharmacological treatments, with glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists representing key innovations. Semaglutide, a GLP-1 receptor agonist, and tirzepatide, a novel dual agonist targeting both GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors, have shown remarkable efficacy in improving glycemic control and promoting weight loss. This review synthesizes the latest clinical evidence on the efficacy and safety of semaglutide and tirzepatide in the management of obesity and T2D, highlighting the findings from recent pivotal trials. In patients with T2D, semaglutide has consistently demonstrated superior glycemic control and weight loss compared to traditional therapies, as evidenced by the SUSTAIN trials [1]. Similarly, tirzepatide has emerged as a more efficacious option, with the SURPASS trials demonstrating greater reductions in HbA1c and more substantial weight loss compared to semaglutide. This positions tirzepatide as a potential first-line therapy for T2D.[2]. Both therapies have shown a favorable safety profile, with gastrointestinal side effects being the most common, and cardiovascular benefits observed in both drug classes. Given their dual mechanism of action, tirzepatide has shown unique potential in addressing both glycemic control and obesity, with emerging evidence supporting its use in non-diabetic patients with obesity [3].This review highlights the potential of these agents to revolutionise the management of obesity and T2D, with tirzepatide emerging as a promising next-generation treatment for metabolic diseases.

23 November 2024 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AMAdrianna Muciek
Adrianna Muciek
MMMartyna Mocarska
Martyna Mocarska
AOAnna Orłowska
Anna Orłowska
KSKatarzyna Strakowska
Katarzyna Strakowska
LOLaura Opalska
Laura Opalska
NNNicole Nitschke
Nicole Nitschke
Nijmegen breakage syndrome (NBS) is a rare autosomal recessive defect of immunity, characterised by chromosomal instability and radiation sensitivity with a high predisposition to malignancy. The clinical manifestations of this condition include microcephaly, combined immunodeficiency, growth retardation and a range of additional abnormalities, including facial, skeletal and skin anomalies (such as café au lait spots and vitiligo). It is estimated that 40% of patients will develop cancer before reaching the age of 21 years. [1-2] The aetiology of this syndrome can be attributed to a mutation in the NBS1 gene, which is localised on chromosome 8q21 and is responsible for the production of the protein nibrin. [3] The most common mutation responsible for NBS (c.657_661del5) is consistent with a founder effect, with the majority of registered patients originating from Central and Eastern Europe and the largest cohort diagnosed in Poland. [4] This article provides an overview of Nijmegen breakage syndrome (NBS), including epidemiology, symptoms, diagnostic pathway and patient management, as well as treatment options. The objective of this study is to enhance awareness of this condition in order facilitate an early diagnosis and screening for malignancy in patients.

5 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AMAnna Maryńczak
Anna Maryńczak
MMMartyna Mocarska
Martyna Mocarska
AOAnna Orłowska
Anna Orłowska
KSKatarzyna Strakowska
Katarzyna Strakowska
LOLaura Opalska
Laura Opalska
KKKarolina Krowiak
Karolina Krowiak
Temporomandibular disorder (TMD) encompasses various conditions affecting the masticatory muscles, temporomandibular joints (TMJs), and related structures. Due to the complexity of the etiology, the diagnosis and management of TMD remain a challenge where consensus is still lacking in many aspects. TMD is characterized by a wide range of symptoms - from disorders strictly resulting from impaired joint function, such as restricted jaw movement and joint sounds, to less obvious manifestations including headache, otologic symptoms, and retro-orbital pain. Treatment of TMD requires an individual approach to each patient and includes physiotherapy, dental or orthodontic care, and in some cases pharmacological or surgical treatment.

27 December 2024 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AMAdrianna Muciek
Adrianna Muciek
MMMartyna Mocarska
Martyna Mocarska
AOAnna Orłowska
Anna Orłowska
KSKatarzyna Strakowska
Katarzyna Strakowska
LOLaura Opalska
Laura Opalska
NNNicole Nitschke
Nicole Nitschke
Alzheimer's disease represents one of the most significant challenges in the field of neurology, affecting millions of individuals worldwide. In pursuing efficacious treatments, lecanemab has emerged as a promising therapeutic option. This pioneering monoclonal antibody targets and reduces amyloid-beta plaques in the brain, a defining feature of Alzheimer's disease. By addressing one of the fundamental causes of the disease, lecanemab represents a novel approach to slowing its progression. On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting marketing authorisation for Leqembi® (whose active substance is lecanemab). This recommendation is specifically directed towards patients with early-onset Alzheimer's disease who are non-carriers or heterozygotes for the apolipoprotein E ε4 (ApoE ε4) allele, thereby underscoring the drug's efficacy tailored to specific genetic profiles (Committee for Medicinal Products for Human Use, 2024). The CHMP's approval is a testament to the extensive research and clinical trials that have demonstrated the efficacy and safety of Leqembi® (Lecanemab). This narrative review aims to provide a comprehensive examination of these aspects and offer a detailed understanding of the potential impact of this treatment on the management of early Alzheimer's disease.

6 August 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
NNNicole Nitschke
Nicole Nitschke
MMMartyna Mocarska
Martyna Mocarska
AOAnna Orłowska
Anna Orłowska
KSKatarzyna Strakowska
Katarzyna Strakowska
LOLaura Opalska
Laura Opalska
JMJan Mencel
Jan Mencel
Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. It affects a significant portion of the global population and often leads to a diminished quality of life. Despite its relatively high prevalence, the exact cause of IBS remains unclear, making effective treatment challenging. Traditional approaches, including dietary modifications, fiber supplements, and antispasmodic medications, have offered relief for some but not all patients. In recent years, new treatment strategies have emerged, targeting the underlying mechanisms believed to contribute to IBS. These include gut-brain axis therapies such as cognitive behavioural therapy (CBT) and hypnotherapy, microbiome-based treatments like faecal microbiota transplantation (FMT) and targeted probiotics, and novel pharmacological agents aimed at modulating serotonin signalling and intestinal motility. Advances in personalized medicine are also playing a growing role, enabling clinicians to tailor treatments based on individual symptom profiles and microbiome composition. These developments represent a promising shift toward more effective and patient-centred management of IBS.